DSIP (Delta Sleep-Inducing Peptide): Why the FDA Panel Said No

Grade CRejected by PCAC

The one they turned down

At the July 2026 advisory committee meeting, seven peptides were reviewed. Six were recommended for the 503A bulks list. DSIP, listed as emideltide, was voted down 6 to 7 with one abstention. It is the only rejection in the set.

The short version

A nine amino acid peptide first isolated from rabbit brain in the 1970s.
Named for an observed sleep effect that has proved difficult to reproduce.
Fifty years of intermittent research have not produced a convincing human evidence base.
The only compound the FDA panel declined to recommend in July 2026.

Why the rejection is the most useful thing on this page

It is easy to read the July 2026 hearing as a rubber stamp, since six of seven passed. The DSIP vote is the evidence against that reading. The committee looked at seven compounds and drew a line at one of them, which means the other six recommendations reflect an actual judgement rather than a blanket wave-through.

It also means that if you see DSIP being marketed as newly available alongside BPC-157 and TB-500, whoever is selling it either has not read the outcome or is counting on you not having.

What the research shows

DSIP was named for an effect observed when brain material from sleeping rabbits was transferred to other animals. Subsequent decades of work have produced inconsistent findings, and the peptide has never established a reliable hypnotic effect in humans. It has been examined for pain, stress response and withdrawal with similarly mixed results.

What this will not do

It will not reliably improve your sleep on the strength of published human evidence.
It will not become available through the process just concluded, because it was rejected.
It will not fix untreated sleep apnea or a schedule problem.

Full library · Safety and sourcing · Reconstitution calculator · Compound index